JP2017513810A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017513810A5 JP2017513810A5 JP2016553568A JP2016553568A JP2017513810A5 JP 2017513810 A5 JP2017513810 A5 JP 2017513810A5 JP 2016553568 A JP2016553568 A JP 2016553568A JP 2016553568 A JP2016553568 A JP 2016553568A JP 2017513810 A5 JP2017513810 A5 JP 2017513810A5
- Authority
- JP
- Japan
- Prior art keywords
- dimethyl
- dienyl
- octa
- benzoquinone
- pentyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- -1 6- (3,7-Dimethyl-octa-2,6-dienyl) -5-hydroxy-3-pentyl-2-methoxycarbonyl- [1,4] benzoquinone 6- (3,7-Dimethyl-octa-2,6-dienyl) -5-hydroxy-3-pentyl-2-ethylamino- [1,4] benzoquinone Chemical compound 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010072170 Skin wound Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000036560 skin regeneration Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- OYTOKPDENGQNLG-UHFFFAOYSA-N CC(=C/CC=1C(C(=C(C(C1O)=O)CCCCC)C=1C(C(=C(C(C1CCCCC)=O)O)CC=C(CCC=C(C)C)/C)=O)=O)CCC=C(C)C Chemical compound CC(=C/CC=1C(C(=C(C(C1O)=O)CCCCC)C=1C(C(=C(C(C1CCCCC)=O)O)CC=C(CCC=C(C)C)/C)=O)=O)CCC=C(C)C OYTOKPDENGQNLG-UHFFFAOYSA-N 0.000 claims 1
- IBISNRABPRDDBD-UHFFFAOYSA-N CC(=CCC1=C(C(C(=C(C1=O)NCC(C)(C)C)CCCCC)=O)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C(C(=C(C1=O)NCC(C)(C)C)CCCCC)=O)O)CCC=C(C)C IBISNRABPRDDBD-UHFFFAOYSA-N 0.000 claims 1
- IMTDOEUZJAJJQR-UHFFFAOYSA-N CC(=CCC1=C(C(C(=C(C1=O)NCCC(C)C)CCCCC)=O)O)CCC=C(C)C Chemical compound CC(=CCC1=C(C(C(=C(C1=O)NCCC(C)C)CCCCC)=O)O)CCC=C(C)C IMTDOEUZJAJJQR-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000006323 alkenyl amino group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000006319 alkynyl amino group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14156954.1A EP2913321B1 (en) | 2014-02-27 | 2014-02-27 | Novel cannabigerol derivatives |
| EP14156954.1 | 2014-02-27 | ||
| PCT/EP2015/053032 WO2015128200A1 (en) | 2014-02-27 | 2015-02-12 | Novel cannabigerol derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513810A JP2017513810A (ja) | 2017-06-01 |
| JP2017513810A5 true JP2017513810A5 (enExample) | 2018-09-20 |
| JP6619349B2 JP6619349B2 (ja) | 2019-12-11 |
Family
ID=50189543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553568A Active JP6619349B2 (ja) | 2014-02-27 | 2015-02-12 | 新規なカンナビゲロール誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9802880B2 (enExample) |
| EP (1) | EP2913321B1 (enExample) |
| JP (1) | JP6619349B2 (enExample) |
| KR (1) | KR102422492B1 (enExample) |
| CN (1) | CN106061937B (enExample) |
| AU (1) | AU2015222384B2 (enExample) |
| BR (1) | BR112016019891B1 (enExample) |
| CA (1) | CA2937275C (enExample) |
| DK (1) | DK2913321T3 (enExample) |
| ES (1) | ES2894760T3 (enExample) |
| IL (1) | IL247149B (enExample) |
| MX (1) | MX358084B (enExample) |
| RU (1) | RU2684913C2 (enExample) |
| WO (1) | WO2015128200A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3122714A1 (en) | 2018-12-11 | 2020-06-18 | Emerald Health Pharmaceuticals Inc | Cannabigerol quinone acid and salts thereof |
| US12084407B2 (en) | 2019-11-26 | 2024-09-10 | Canopy Growth Corporation | Cannabigerol derivatives and use thereof as cannabinoid receptor modulators |
| GR1010219B (el) * | 2021-01-22 | 2022-04-08 | Ekati Alchemy Lab Sl, | Φαρμακευτικα προϊοντα βασισμενα σε εστερες κανναβινοειδων οξεων |
| WO2023059640A1 (en) * | 2021-10-06 | 2023-04-13 | Juva Life, Inc. | Cannabigeroquinone compounds, compositions including such compounds, and uses of such compounds and compositions |
| US20250241934A1 (en) * | 2024-01-22 | 2025-07-31 | Miralogx Llc | Synthetic Cannabigerol Quinone Analogs and Pharmaceutical Compositions Containing Same for Treating Neurological Disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI102273B (fi) * | 1989-09-11 | 1998-11-13 | Eisai Co Ltd | Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö |
| CA2570501A1 (en) * | 2004-06-18 | 2006-01-26 | Gergely Szakacs | Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells |
| EP2551255B1 (en) * | 2010-03-26 | 2017-11-08 | Vivacell Biotechnology España, S.L | Cannabinoid quinone derivatives |
-
2014
- 2014-02-27 DK DK14156954.1T patent/DK2913321T3/da active
- 2014-02-27 EP EP14156954.1A patent/EP2913321B1/en active Active
- 2014-02-27 ES ES14156954T patent/ES2894760T3/es active Active
-
2015
- 2015-02-12 US US15/122,160 patent/US9802880B2/en active Active
- 2015-02-12 JP JP2016553568A patent/JP6619349B2/ja active Active
- 2015-02-12 CN CN201580010458.8A patent/CN106061937B/zh active Active
- 2015-02-12 BR BR112016019891-3A patent/BR112016019891B1/pt not_active IP Right Cessation
- 2015-02-12 KR KR1020167025830A patent/KR102422492B1/ko not_active Expired - Fee Related
- 2015-02-12 CA CA2937275A patent/CA2937275C/en active Active
- 2015-02-12 MX MX2016010952A patent/MX358084B/es active IP Right Grant
- 2015-02-12 AU AU2015222384A patent/AU2015222384B2/en not_active Ceased
- 2015-02-12 RU RU2016132415A patent/RU2684913C2/ru active
- 2015-02-12 WO PCT/EP2015/053032 patent/WO2015128200A1/en not_active Ceased
-
2016
- 2016-08-07 IL IL24714916A patent/IL247149B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230235A1 (ar) | عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون | |
| RU2016137668A (ru) | Новые производные каннабидиол-хинона | |
| JP2019522055A5 (enExample) | ||
| PH12019500214A1 (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| JP2012097105A5 (enExample) | ||
| EP4275748A3 (en) | Compositions and methods for treating cns disorders | |
| JP2019524883A5 (enExample) | ||
| CY1119575T1 (el) | Ενωσεις υποκατεστημενης βενζαλδεϋδης και μεθοδοι για τη χρηση τους στην αυξηση της οξυγονωσης του ιστου | |
| JP2017531688A5 (enExample) | ||
| UA114944C2 (uk) | Піридинільні і конденсовані піридинільні похідні триазолону | |
| JP2013540713A5 (enExample) | ||
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2016513130A5 (enExample) | ||
| PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| RU2015135824A (ru) | Бициклические соединения пиримидона в качестве ингибиторов lp-pla2 | |
| RU2016132415A (ru) | Новые производные каннабигерола | |
| JP2016513696A5 (enExample) | ||
| JP2016511753A5 (enExample) | ||
| EA201990455A1 (ru) | КОНДЕНСИРОВАННОЕ ТРИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ γ-АМИНОКИСЛОТЫ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ | |
| MX378591B (es) | Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico | |
| JP2017538712A5 (enExample) | ||
| JP2018537513A5 (enExample) | ||
| JP2016528273A5 (enExample) | ||
| JP2017508817A5 (enExample) | ||
| RU2017141446A (ru) | Энантиомеры 2-гидроксипроизводных жирных кислот |